...The Problem Joint Ventures do not always work and when they do they don’t work indefinitely. What Eli Lilly and Ranbaxy are facing now is the dilemma of rather to continue with their JV, Eli Lilly Ranbaxy, or should they separate and continue each one by its own means. The situation represents both a problem and an opportunity to both companies, as there are important trade-offs to be considered before any decision is taken. The Environment In the last decade the environment for the pharmaceutical industry changed radically in India. Before the 1990’s there were no regulations for patent recognition and the government had an active role in establishing drug prices through the DPCO, which were situated amongst the lowest in the world. Profit margins were also regulated at around 6% of sales. As a result many of the multinationals started exiting the Indian market. As India enter the GATT and the WTO in 1994 patent protection would become active in India from 2004-2005. In the international arena, patent regulation was also little by little becoming stronger and many of the big players were going through M&A processes that further increased the sales concentration in few companies. These companies had a hard time competing with local laboratories that produced generic drugs with no R&D expenses and at a fraction of the price. Eli Lilly Ranbaxy portraits the example of the traditional JV in which Ranbaxy, a company from less-industrialized country, offered the knowledge and...
Words: 1256 - Pages: 6
...A “Calibrated Approach”: Pharmaceutical FDI and the Evolution of Indian Patent Law Web version: August 2007 Authors: Katherine Connor Linton and Nicholas Corrado1 Abstract India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs) have responded to India’s movement towards compliance with the W TO intellectual property agreement, TRIPS, by increasing the quantity and quality of foreign direct investment (FDI) in the areas of pharmaceutical research and development (R&D) and manufacturing. By contrast, MNCs have adopted a more cautious attitude toward the patenting and commercialization of new pharmaceutical products in India, waiting to see how Indian courts and patent offices interpret the new laws, and awaiting the enactment of longdebated data protection legislation. The ultimate success of the Indian “calibrated approach” to fostering the domestic industry and access to medicine while also addressing international IP requirements remains to be seen. 1 Katherine Connor Linton (katherine.linton@usitc.gov) is the International Trade Analyst for Intellectual Property and Nicholas Corrado was a law student intern in the Office of Industries of the U.S. International Trade Commission (USITC). The views expressed are those of Ms. Linton and...
Words: 6873 - Pages: 28
...Bottom of Form |Read full version essay Case Analysis : Pharma Industry | |Case Analysis : Pharma Industry | |Print version essay is available for you! You can search Free Term Papers and College Essay Examples written by students!. | |Join Essays24.com and get instant access to Case Analysis : Pharma Industry and over 30,000 other Papers and Essays | | | | | |Category: Business | |Autor: anton 06 June 2011 ...
Words: 4303 - Pages: 18
...Chapter 1 expanding abroad: motivations, means, and mentalities Case 1-1 Cameron Auto Parts * Alex Cameron got the family biz when graduated in 2001, when the American economy fell into a recession * History * Auto Pact, big three ship car parts between Canada & US, with tariff free * Cameron focus on small engine parts and auto accessories * Car Sales dropped in 2000, because declining North America and entry of Japanese * High pressure for modernization and cost reduction * Operational survival: cut workforce, overtime, part-time, subcontracting * Recovery and diversification * The short-term future seemed positive, but the popularity of Japanese car forced it to diversify * Working as an OEM Cameron did little to be innovative * Alex brought in a team of designers, concentrating on developing products with a wider ‘non-automotive’ market appeal * The first year no progress, Alex lured away a key engineer from the Canadian firm, and mid-2003, developed its own line of flexible couplings * Marketing the new product * Hired eight field sales representatives, stress product quality, service and speed of delivery, but not price. * Financing plant capacity * Increasing sales of flexible couplings required a new separate plant, but the financial position is not strong enough to support it * Foreign markets * Took a European Patent * A licensing opportunity ...
Words: 18260 - Pages: 74
...[pic] Course Syllabus Managing International Business Graduate Program in General Management Class of Executive July 2008 Course Leader: Handry Satriago Oct 2009 – Feb 2010 IPMI Business School Graduate Program The Indonesian Institute for Management Development Jakarta, Indonesia Course Name : Managing International Business (MIB) Class : Executive Program, July 2008 Facilitators : Handry Satriago (Course Leader) Guest Speakers : Subject to confirmation from the guest speakers - Riri Riza/Mira Lesmana, MILES Film (Session 5) Topic: Indonesia Movie Industry - Richard Matalon, President Director L’Oreal Indonesia (Session 12) Topic: L’Oreal strategy entering Indonesia - Vikram Reddy, GM Four Seasons Hotel Jakarta (Session 16) Topic: Four Seasons Global Strategy Background Companies today confront an increasing array of choices of markets, of locations for value adding activities, and of modes of crossing borders. This course focuses on the international dimensions of strategy and organization, and provides a framework for formulating strategies in an increasingly complex world economy, and for making those strategies work effectively. Operation in an international environment gives the manager access to new markets, additional natural resources, and low-cost-factor...
Words: 6165 - Pages: 25
...Industry Snapshot The Indian pharmaceutical industry is highly dynamic and offers great opportunities for both domestic and foreign companies. The industry is estimated to have generated revenue worth US$ 13.1 billion in FY 2011, according to a new Research and Market’s report, “Indian Pharma Sector Forecast 2014.” India will emerge as a leading global player in pharmaceutical industry by 2020, securing a place among the top five major global markets, according to Ikon Marketing Consultant (IMC). Also, Associated Chambers of Commerce and Industry (Assocham) has said it expects the Indian pharmaceutical industry to reach US$ 20 billion by 2015, making it one of the world's top 10 pharmaceuticals markets. India has a strong local manufacturing base and domestic players are developing substantial international presence. Healthcare is also one of the largest service sector industries in India, in terms of revenue and employment. Rising health awareness and increasing government expenditure on healthcare sector is driving growth in the sector. Medical tourism and health insurance are also on a rise, with significant growth in healthcare sector and establishment of large number of hospitals, both public and private. The Indian healthcare industry, estimated at US$ 50 billion, is expected to reach over US$ 75 billion by 2012, and US$ 100 billion by 2015. Talent Challenges While specialised talent is critical for any knowledge industry, it is more so within the pharmaceuticals industry...
Words: 6445 - Pages: 26
...Pharmaceuticals and Life Sciences Global pharma looks to India: Prospects for growth Table of contents Introduction 03 Background 04 A fast growing economy An expanding pharmaceutical market Government-provided healthcare improving, but private healthcare dominates Domestic market overview 09 Background Consolidation underway, despite challenges Contract manufacturing Vaccines Over the counter market holds significant potential Reaching the untapped rural market Growing Research & Development 15 Overview Clinical trials Biotech and biosimilars on track for growth Other growth areas Bioinformatics 20 Stem cell research Medical devices Global Pharma’s evolving business models and options in India 23 Background Export-oriented business (Contract Research and Manufacturing Services) Licensing Franchising Joint ventures Wholly-owned subsidiaries Practical concerns 27 Infrastructure Tax environment Counterfeiting Intellectual property Conclusion 30 Related reading: Pharma 2020 31 References 32 Acronyms 38 Introduction The pharmaceutical industry’s main markets are under serious pressure. North America, Europe and Japan jointly account for 82% of audited and unaudited drug sales; total sales reached US$773 billion in 2008, according to IMS Health. Annual growth in the European Union (EU) has slowed to 5.8%, and sales are increasing at an even more sluggish rate...
Words: 17333 - Pages: 70
...9-707-441 REV: MARCH 30, 2010 TARUN KHANNA KRISHNA PALEPU CLAUDINE MADRAS Teva Pharmaceutical Industries, Ltd In Israel we have a 1970s song based on a poem from 1953 by Amir Gilboa about Theodor Herzl.1 It has a line in it about Herzl: “Suddenly a man rises in the morning, feels he is a people, and starts walking.” That is exactly what Hurvitz did. Suddenly he woke up in the morning, feels he is a giant world class company, and starts walking. No one, aside from Herzl, has accomplished anything as remotely as impressive in this country as Hurvitz. It was impossible, a million to one odds at best, and he still did it. He woke up one morning and started walking. — Ori Hershkovitz, equity analyst at Tel Aviv-based Leader & Company The markets had not been kind to Teva Pharmaceutical during the first half of 2006. The stock had plunged nearly 30% from January 1 to June 30, erasing billions of dollars from the company’s market capitalization. Even good news, such as reports in July of Teva’s wildly successful introduction of generic Zocor—the largest blockbuster drug ever to go off-patent—had failed to boost the stock significantly. Since nearly every retirement fund and mutual fund in Israel invested in Teva, this drop had been felt throughout the population, in effect amounting to every Israeli family losing NIS 3000, or $675.1 Teva was more than the world’s leading producer of generic pharmaceuticals (see Exhibit 1 for financials). It represented the gold standard of business...
Words: 12524 - Pages: 51
...Introduction :- Human Resource Management (HRM) is a relatively new approach to managing people in any organisation. People are considered the key resource in this approach. it is concerned with the people dimension in management of an organisation. Since an organisation is a body of people, their acquisition, development of skills, motivation for higher levels of attainments, as well as ensuring maintenance of their level of commitment are all significant activities. These activities fall in the domain of HRM. Human Resource Management is a process, which consists of four main activities, namely, acquisition, development, motivation, as well as maintenance of human resources. Scott, Clothier and Spriegel have defined Human Resource Management as that branch of management which is responsible on a staff basis for concentrating on those aspects of operations which are primarily concerned with the relationship of management to employees and employees to employees and with the development of the individual and the group. Human Resource Management is responsible for maintaining good human relations in the organisation. It is also concerned with development of individuals and achieving integration of goals of the organisation and those of the individuals. Northcott considers human resource management as an extension of general management, that of prompting and stimulating every employee to make his fullest contribution to the purpose of a business. Human resource management...
Words: 9061 - Pages: 37
...APPENDIX: Kellogg Consulting Club Practice Cases While most cases require multiple analytical techniques, the category indicates where the candidate will likely spend most of the time. SECTION I: Sample Case Interviews 1. 2. New Drug Launch Prozac SECTION II: Profitability/Operations 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. Shamrock Chemical Chilled Beverages Distilled Spirits Commodity Manufacturer Snack Food Conglomerate ROIC Increase Agricultural Equipment Manufacturing Paint Manufacturer Super Regional Bank Local Banking Demand Cement Manufacturer Beverage Company Candy Company SECTION III: Industry Analysis/Growth 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. Direct Mail Retailer Selective Binding Case Iberia Gasoline Pricing Pipeline Company Permanent Light Bulbs Aluminum Can Manufacturer Science Industry Information Services Company Meat Packing Industry Video Games Merger Candidate in Chemical Industry Machine Loading Case Telecommunications Diversification Packaging Material Manufacturer Page 34 SECTION IV: Market Entry/Expansion/Investment 30. 31. 32. 33. 34. 35. 36. Corn Feed Company Buenos Aires ENT Consulting Firm (I) Concrete Manufacturer Healthcare Company Gas Manufacturer Vitamin Manufacturer Entry into China SECTION V: Market Sizing/Estimation/Brainteasers 37. 38. 39. 40. 41. 42. 43. Cigar Bar New Magazine Piano Tuners Cars in the Chicago Loop Chewing Gum Market Golf ball Market Entry Oil Refining Industry SECTION VI: Miscellaneous ...
Words: 23126 - Pages: 93
...(FDA) approved facilities. US accounts for one-fourth of the Indian drug exports. The share of Indian pharma companies in the total approvals for generic drugs called Abbreviated New Drug Application (ANDA) has risen steadily. From 32 per cent in 2009, it went up to 38.5 per cent in 2013. Increasing share of Indian companies in total ANDAs approved by the USFDA can be attributed to increase spending by them for research and development (R&D) activities. As per CMIE’s database, the industry’s R&D expenses to sales ratio jumped to around five per cent in 2012-13 from around three per cent in 2003-04. The export of drugs from India is expected to grow by 4.2 per cent to USD 15.2 billion in 2013-14. Around USD 16.3 billion of drugs are likely to be shipped from the country in 2014-15. This translates into a growth of 7.3 per cent. In 2015-16, drug exports from India are expected to touch USD 17.5 billion, 7.7 per cent higher than the previous year. Many developing countries like Latin America and Africa have also opened doors for generic drugs due to ageing population, rising income levels, increasing lifestyle diseases and low penetration...
Words: 11886 - Pages: 48
...Emerging market report 2007 Disclaimer PricewaterhouseCoopers has exercised professional care and diligence in the collection and processing of the information in this report. However, the data used in the preparation of this report (and on which the report is based) was provided by third-party sources. This report is intended to be of general interest only and does not constitute professional advice. PricewaterhouseCoopers makes no representations or warranties with respect to the accuracy of this report. PricewaterhouseCoopers shall not be liable to any user of this report or to any other person or entity for any inaccuracy of information contained in this report or for any errors or omissions in its content, regardless of the cause of such inaccuracy, error or omission. Furthermore, to the extent permitted by law, PricewaterhouseCoopers, its members, employees and agents accept no liability and disclaim all responsibility for the consequences of you or anyone else acting, or refraining from acting, in relying upon the information contained in this report or for any decision based on it, or for any consequential, special, incidental or punitive damages to any person or entity for any matter relating to this report even if advised of the possibility of such damages. The member firms of the PricewaterhouseCoopers network (www.pwc. com) provide industry-focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders...
Words: 6564 - Pages: 27
...marijuana and how it became illegal. Then, it will attempt to examine and illustrate the many valuable, and beneficial qualities that marijuana has. Relying on the facts found to ultimately come to a conclusion on whether or not legalization would positively effect our country. Introduction Background Information The legalizing of marijuana for both recreational and medical purposes will have significant benefits for smokers and non-smokers, the economy, and the population. Currently any production, sale, distribution, or consumption of the drug marijuana is illegal in forty-eight states in the nation. Legalizing marijuana in this situation would mean executing the same or similar laws as are imposed on to alcohol. “On November 6, 2012, Colorado and Washington became the first states to legalize the sale and possession of cannabis for recreational use since the Marijuana Tax act of 1937 when they passed Colorado Amendment 64 and Washington Initiative 502” (Szalavitz). The few states that have legalized marijuana are instituting practices to integrate the substance into society. To continue, consumption of marijuana would be illegal as well as the purchase of the substance by minors under the age of 21. Driving or performing certain tasks under the influence of the drug would be illegal and result in criminal consequences. The unlicensed sale of the drug, or any sale to minors will be illegal as well. The personal production or growth of the substance would be legal...
Words: 3369 - Pages: 14
...Ghemawat’s “AAA” Global Strategy Framework Ghemawat so-called AAA framework offers three generic approaches to global value creation. Adaptation strategies strategies that seek to increase revenues and market share by tailoring one or more components of a firm’s business model to suit local requirements or preferences. Aggregation strategies focus on achieving economies of scale or scope by creating regional or global efficiencies; they typically involve standardizing a significant portion of the value proposition and grouping together development and production processes. Arbitrage is about exploiting economic or other differences between national or regional markets, usually by locating separate parts of the supply chain in different places. Adaptation Adaptation—creating global value by changing one or more elements of a company’s offer to meet local requirements or preferences—is probably the most widely used global strategy. The reason for this will be readily apparent: some degree of adaptation is essential or unavoidable for virtually all products in all parts of the world. The taste of Coca-Cola in Europe is different from that in the United States, reflecting differences in water quality and the kind and amount of sugar added. The packaging of construction adhesive in the United States informs customers how many square feet it will cover; the same package in Europe must do so in square meters. Even commodities such as cement are not immune: its pricing in different...
Words: 5113 - Pages: 21
...meal planning, medication, and regular physical activity. It sounds too good to be true on reversing Type II diabetes through exercise and healthy eating is true. While certain lifestyle changes are key to managing diabetes, whether you can actually turn back time so that it's like you never had diabetes is a different matter. That depends on how long you've had the condition, how severe it is, and your genes. "The term 'reversal' is used when people can go off medication but still must engage in a lifestyle program in order to stay off," (Ann Albright, 2015). Type 2 is the most common form of diabetes and can be diagnosed at any age. It is most commonly seen in adults. Type 2 diabetes accounts for about 90 to 95 percent of all diagnosed cases of diabetes, more than 29.1 million people or 9.3% of the U.S. population have diabetes. Chapter 1 History of Diabetes Now with a better understanding of Diabetes, the background of the disease is very important. In the first century A.D. a Greek, Aretaeus, described the destructive nature of the affliction which he named "diabetes" from the Greek word for “siphon”. “For fluids do not remain in the body, but use the body only as a channel through...
Words: 7806 - Pages: 32
